What the FDA labels say about taking them together
Amiloride and amlodipine/valsartan
Amlodipine/valsartan's FDA label of February 17, 2026 names amiloride in its drug interactions section; amiloride's label does not name amlodipine/valsartan itself but warns about its class (ARBs (angiotensin II receptor blockers), Calcium channel blockers, Calcium channel blockers (dihydropyridines)). The amlodipine/valsartan label: “Valsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics, potassium supplements, salt substitutes containing …”
Check it at the source: the amiloride FDA label on DailyMed (effective May 5, 2023, Padagis US LLC); the amlodipine/valsartan FDA label on DailyMed (effective February 17, 2026, Novartis Pharmaceuticals Corporation).
What does the amiloride label say about amlodipine/valsartan?
Amiloride's label does not name amlodipine/valsartan itself; it warns about its class (ARBs (angiotensin II receptor blockers), Calcium channel blockers, Calcium channel blockers (dihydropyridines)):
Amiloride label, warningsThe risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus. (See PRECAUTIONS, Drug Interactions .) Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities.
Amiloride label, drug interactionsDrug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased.
Source: FDA drug label (amiloride hydrochloride), Padagis US LLC, effective May 5, 2023 (SPL set 2b70cf0c-45be-428f-b396-5001ed4e30fc), via openFDA; the full label on DailyMed
What does the amlodipine/valsartan label say about amiloride?
Amlodipine/valsartan label, drug interactionsValsartan Agents Increasing Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.
Source: FDA drug label (Exforge), Novartis Pharmaceuticals Corporation, effective February 17, 2026 (SPL set d0caec89-96ec-411d-a933-63eda74a6da7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
These are the ingredient's own label sentences, repeated in a combination product's or a biosimilar's label. The ingredient pair sets them out with both labels side by side.
Both medicines on the record
| Amiloride | Amlodipine/valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | High blood pressure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.190 per tablet 5 mg tablet | $0.330 per unit 10-160 mg |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once